http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-526133-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D225-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D225-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2002-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7b3991f24e8aac2e85290c6ad13f4db http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2d695c7729763ac10c3380eeb91a4bf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7537746b1c30323d10ed645653d9bb9c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b525af516751c29096d3f19667e9f26 |
| publicationDate | 2005-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-526133-A |
| titleOfInvention | Geldanamycin derivative and method of treating cancer using same |
| abstract | A geldanamycin derivative of formula I, or a pharmaceutically acceptable salt thereof, is described to be used in the manufacture of a medicament for treating or preventing cancer. When n=1, each of R1 and R2 is disclosed to be hydrogen, and, when n=0, a double-bond exists between C4 and C5. R3 and R4 are stated to be hydrogen or hydroxyl; wherein, when R3 is hydrogen, R4 is hydroxyl, and when R3 is hydroxyl, R4 is hydrogen. R5 is hydrogen or a group of formula II, wherein each of R6, R7, and R8 is independently selected from the group consisting of hydrogen, halo, azido, nitro, a C1-C8 alkyl, a C1-C8 alkoxy, aryl, cyano, and NR10R11, wherein each of R10 and R11 is independently selected from the group consisting of hydrogen and a C-1-C3 alkyl. The derivative is explained to exhibit significant preliminary in vitro activity, particularly significant oral in vitro activity. |
| priorityDate | 2001-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.